arGEN-X Awarded €1.5 Million IWT Grant to Accelerate Pre-Clinical Antibody Development
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), has announced that it has received a €1.5 million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space.
Today’s award is the second grant that arGEN-X has received from the IWT. In October 2009, the Company received €1.3 million to develop and validate the SIMPLE Antibody™ platform, a pioneering approach to therapeutic human mAb generation.
In less than a year, the SIMPLE Antibody™ platform has demonstrated phenomenal productivity as a discovery engine, yielding therapeutic grade mAbs with highly differentiated functional attributes. SIMPLE Antibody™ candidates have unprecedented functional diversity against soluble, cell surface and highly conserved targets. Importantly, these mAbs do not require time-consuming engineering to ensure their gold standard affinities and potencies.
The power of the SIMPLE Antibody™ approach has allowed arGEN-X to progress its research porfolio into pre-clinical development in record time. Its most advanced mAb candidate ARGX-109 has ultra-high potency against IL-6, a cytokine playing an important role in autoimmune, inflammation and oncology indications.
arGEN-X’s two other development programs also address targets of high functional relevance in inflammation and oncology. All SIMPLE Antibody™ candidates developed by arGEN-X to date show outstanding manufacturability, effectively reducing the transition time from discovery to development.
Prof. Dr. Hans de Haard, CSO of arGEN-X commented: “Today’s news highlights the power of our proprietary SIMPLE Antibody™ platform when compared to established human antibody technologies. Having already successfully validated the platform, we will apply this second IWT grant to the pre-clinical development of our lead product candidate ARGX-109 and drive forward two further therapeutic programs. Our rapid evolution and progress has reinforced our confidence in our technology’s ability to tranform the human therapeutic antibody landscape.”
This grant will be used to accelerate pre-clinical development of the lead program, ARGX-109 and two further therapeutic mAb programs. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody™ platform and are being developed by the Company to target the inflammation/oncology space.
Today’s award is the second grant that arGEN-X has received from the IWT. In October 2009, the Company received €1.3 million to develop and validate the SIMPLE Antibody™ platform, a pioneering approach to therapeutic human mAb generation.
In less than a year, the SIMPLE Antibody™ platform has demonstrated phenomenal productivity as a discovery engine, yielding therapeutic grade mAbs with highly differentiated functional attributes. SIMPLE Antibody™ candidates have unprecedented functional diversity against soluble, cell surface and highly conserved targets. Importantly, these mAbs do not require time-consuming engineering to ensure their gold standard affinities and potencies.
The power of the SIMPLE Antibody™ approach has allowed arGEN-X to progress its research porfolio into pre-clinical development in record time. Its most advanced mAb candidate ARGX-109 has ultra-high potency against IL-6, a cytokine playing an important role in autoimmune, inflammation and oncology indications.
arGEN-X’s two other development programs also address targets of high functional relevance in inflammation and oncology. All SIMPLE Antibody™ candidates developed by arGEN-X to date show outstanding manufacturability, effectively reducing the transition time from discovery to development.
Prof. Dr. Hans de Haard, CSO of arGEN-X commented: “Today’s news highlights the power of our proprietary SIMPLE Antibody™ platform when compared to established human antibody technologies. Having already successfully validated the platform, we will apply this second IWT grant to the pre-clinical development of our lead product candidate ARGX-109 and drive forward two further therapeutic programs. Our rapid evolution and progress has reinforced our confidence in our technology’s ability to tranform the human therapeutic antibody landscape.”
